Global Erythema Nodosum Market, By Treatment (NSAIDs (Non-Steroidal Anti-Inflammatory Drugs),Systemic Corticosteroids, Oral Potassium Iodide, Others), Diagnosis (Blood Tests, Biopsy, Physical Exam, Others), Symptoms (Painful Bumps, Ankle Swelling, Fatigue, Joint Pain, Fever, Sore Throat, Stomach Pain, Enlarged Lymph Nodes in the Chest, Cough, Weight Loss, Diarrhea, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Injectable, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Erythema Nodosum Market
Erythema nodosum market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.90% in the above mentioned forecast period.
A painful inflammation of the connective tissues beneath the skin's surface is known as erythema nodosum. It's identified by lumps or nodules under the skin that are about an inch in diameter, firm, red, and heated to the touch. The lumps may become a reddish tint over few days and then diminish over the next several weeks. They are most commonly found on the shins, but they can also be found on other parts of your body, such as your arms, legs, and buttocks. Erythema nodosum can arise in the presence or absence of another medical condition. Medication, fungal infections, infectious mononucleosis, sarcoidosis, Behcet's disease, and normal pregnancy are all connected to erythema nodosum. Others symptoms of this condition include ankle swelling, fatigue, joint pain, fever, sore throat, stomach pain, enlarged lymph nodes in the chest, cough, weight loss and diarrhea.
The rise in the prevalence of erythema nodosum and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, growing government funding and rising initiatives by public and private organisations to spread awareness about the disease and its available treatment are the factors that will expand the erythema nodosum market. Other factors including growing incidences of tuberculosis, pneumonia, sarcoidosis, throat infection and fungal infection and consumption of medicines such as estrogens, sulfa-related drugs and birth control pills will positively impact the market growth rate.
Rise in the research and development activities and emerging new markets will provide beneficial opportunities for the erythema nodosum market in the forecast period of 2021-2028.
However, high cost of the treatment and complications associated with the disease are the factors that will hinder the market growth. Lack of awareness will further challenge the erythema nodosum market in the forecast period mentioned above.
This erythema nodosum market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the erythema nodosum market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Erythema Nodosum Market Scope and Market Size
The erythema nodosum market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the erythema nodosum market is segmented into NSAIDs (non-steroidal anti-inflammatory drugs), systemic corticosteroids, oral potassium iodide and others.
- On the basis of diagnosis, the erythema nodosum market is segmented into blood tests, biopsy, physical exam, and others.
- On the basis of symptoms, the erythema nodosum market is segmented into painful bumps, ankle swelling, fatigue, joint pain, fever, sore throat, stomach pain, enlarged lymph nodes in the chest, cough, weight loss, diarrhea and others.
- On the basis of dosage, the erythema nodosum market is segmented into tablet, injection and others.
- On the basis of route of administration, the erythema nodosum market is segmented into oral, injectable and others.
- On the basis of end-users, the erythema nodosum market is segmented into clinic, hospital and others.
- The erythema nodosum market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Erythema Nodosum Market Country Level Analysis
The erythema nodosum market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel.
The countries covered in the erythema nodosum market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the erythema nodosum market due to presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Erythema nodosum market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Erythema Nodosum Market Share Analysis
Erythema nodosum market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to erythema nodosum market research.
The major players covered in the erythema nodosum market report are Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Horizon Therapeutics plc., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC, Cipla Inc., Sumitomo Dainippon Pharma Co., Ltd., LEO Pharma A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Zyla Life Sciences, Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Lonza, Dr. Reddy’s Laboratories Ltd., Iroko Pharmaceuticals Inc., Assertio Holdings, Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-